Evogene Ltd.EVGNEarnings & Financial Report
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technolo...
EVGN Q2 2025 Key Financial Metrics
营收
$3.2M
毛利润
$1.6M
营业利润
$-6.1M
净利润
$-7.7M
毛利率
48.8%
营业利润率
-189.0%
净利率
-237.7%
同比增长
40.7%
资金流向
Evogene Ltd. Q2 2025 Financial Summary
Evogene Ltd. reported revenue of $3.2M (up 40.7% YoY) for Q2 2025, with a net profit of $-7.7M (up 22.0% YoY) (-237.7% margin). Cost of goods sold was $1.7M, operating expenses totaled $7.7M.
Key Financial Metrics
| Total Revenue | $3.2M |
|---|---|
| Net Profit | $-7.7M |
| Gross Margin | 48.8% |
| Operating Margin | -189.0% |
| Report Period | Q2 2025 |
Evogene Ltd. Quarterly Revenue & Net Profit History
Evogene Ltd. quarterly results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $3.2M | +40.7% | $-7.7M | -237.7% |
| Q2 2024 | $2.3M | +77.1% | $-9.8M | -428.5% |
利润表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 营收 | $2.3M | $3.2M |
| 同比增长 | 77.1% | 40.7% |
资产负债表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 总资产 | $41.0M | $33.9M |
| 总负债 | $21.0M | $21.6M |
| 股东权益 | $19.9M | $12.4M |
现金流量表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 经营性现金流 | $-9.6M | $-7.5M |